Cencora Expands into Cell and Gene Therapy Support for Health Systems
Event summary
- Cencora launched Cell and Gene Therapy Enablement through Accelerate Pharmacy Solutions to help health systems build and scale CGT programs.
- The service addresses operational readiness, financial confidence, and scalable growth for CGT programs.
- Only 4% of health system pharmacy leaders surveyed feel fully prepared to integrate CGTs, highlighting infrastructure gaps.
- Cencora aims to reduce barriers to care and expand patient access to advanced therapies.
The big picture
Cencora’s move into CGT support aligns with the rapid growth of cell and gene therapies, which require specialized operational and financial infrastructure. With over 35 FDA-approved CGTs and 1,700 clinical trials globally, the service targets a critical gap in health system readiness. The company leverages its existing pharmacy and supply chain expertise to position itself as a key player in this evolving sector.
What we're watching
- Market Adoption
- How quickly health systems will adopt Cencora’s CGT Enablement service given the current low readiness levels.
- Regulatory Dynamics
- Whether the FDA’s approval of more CGTs will accelerate demand for Cencora’s support services.
- Competitive Positioning
- The pace at which Cencora can differentiate itself in the growing CGT support market.
Related topics